Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis, Measles, Mumps, Rubella
Trial Timeline
Aug 1, 2010 → Dec 1, 2012
NCT ID
NCT01188343About Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01188343. Target conditions include Japanese Encephalitis, Measles, Mumps.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01188343 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis